Therapeutical Effect And Mechanism On Chronic Obstructive Pulmonary Disease Of Penehyclidine Hydrochlonride

Background:Chronic obstructive pulmonary disease (COPD) is a medical disease, multiple cured difficult, and the incidence and mortality rates increased year by year. The current study that the incidence of COPD is a mechanism for a variety of reasons led to the chronic airway injury, and does not fully restored Cheng, resulting in airway structure and function changes can be further developed into a chronic pulmonary heart disease or chronic respiratory failure. According to the World Health Organization (WHO) estimates that the global disease causes of death, after heart disease COPD. cerebrovascular disease and acute lung infection, and AIDS together alongside the fourth. It has a serious economic burden as the number of patients with COPD, high mortality, serious harm to people's health and survival period of the disease. To the family and the community, COPD will become Clinical and Experimental Research hot issues with the development of safe, effective and tolerable side effects of anti COPD drugs.Objective :To investigate Ganlixin (DGPS) to rats in the treatment of COPD its possible mechanism.Methods :The experimental rats used to passive smoking and intratracheal injection of lipopolysaccharide combination of methods, COPD induced rat model. The experimental animals were randomly divided into four groups : control group, model group, the positive control group. Ganlixin (DGPS) in the treatment group. For the positive control drug aminophylline. Detection of the rats ingeneral; Arterial blood gas changes; assay of serum hyaluronic acid (Effects of hyaluronan. HA) and laminin (Laminnin LN); Liquid competition detection of tumor necrosis factor-Europium (Tumor Necrosis Factor-Europium. TNF-Europium); Immunohistochemical staining was detected NF-κBp50 number of positive cells and protein expression; lung tissue structure and the general change in optical microscopy and transmission electron microscopy change.Result :The results confirmed that Ganlixin resistant COPD role in rats. Features : COPD can reduce the standards of arterial blood gas PaCO2 and CO2 retention in rats; lower significantly the contents of hyaluronic acid (HA), laminin (LN), tmor necrosis factor-α(TNF-α) level in serum, Ganlixin was statistically significant (P<0.05),compared with the model group. Ganlixin can reduce the number of lung tissue NF-κBp50positive cells and NF-κBp50 protein expression; Histological examination showed the same significant role in the anti-COPD.Conclusion :1. To reproduce successfully a rat model of COPD through two times intratracheal injection of lipopolysaccharide 30 days.2. Ganlixin can significantly low PaCO2 level in experimental rats.3. Ganlixin can reduce significantly hyaluronic acid, laminin, tumor necrosis factor-Europium. Ganlixin inhibit cytokine production, protect residual lung cells play a role in anti-COPD.4. Ganlixin can reduce NF-κBp50 protein expression, Note its anti-inflammatory effects may be passed on the role of NF-κBp50 reduce lunginjury achieve.5. Ganlixin confirmed the cause of COPD Pathological changes have better effect.6. Ganlixin were expected as a new drug for the treatment of COPD clinical, The topics provides a reliable experimental basis for further study.